Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cardiac Biotech Solutions's Enterprise Value is $5.74 Mil.
Cardiac Biotech Solutions's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.32 Mil. Therefore, Cardiac Biotech Solutions's EV-to-FCF for today is -17.84.
The historical rank and industry rank for Cardiac Biotech Solutions's EV-to-FCF or its related term are showing as below:
CBSC's EV-to-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 25.2 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cardiac Biotech Solutions's PE Ratio (TTM) for today is calculated as:
Cardiac Biotech Solutions's share price for today is $0.03269.
Cardiac Biotech Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cardiac Biotech Solutions EV-to-FCF Related Terms
Cardiac Biotech Solutions EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiac Biotech Solutions EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cardiac Biotech Solutions's EV-to-FCF falls into.
Cardiac Biotech Solutions's current Enterprise Value is $5.74 Mil.
Cardiac Biotech Solutions's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiac Biotech Solutions (CBSC) has a EV-to-FCF of -17.84 as of Aug. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' EV-to-FCF too high?
Cardiac Biotech Solutions' current EV-to-FCF is -17.84.
How does Cardiac Biotech Solutions' EV-to-FCF compare to LUCY and NXGL?
Cardiac Biotech Solutions' EV-to-FCF of -17.84 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-FCF is 25.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 25.20, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cardiac Biotech Solutions and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 25.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiac Biotech Solutions's current EV-to-FCF is -17.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current EV-to-FCF of -17.84. The current EV-to-FCF is -17.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current EV-to-FCF is -17.84 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBSC has been successfully added to your 
